Hereditary Spherocytosis: Key Facts and Genetic Basis
Hereditary spherocytosis (HS) is an inherited hemolytic anemia caused by mutations in red blood cell membrane proteins—most commonly ANK1 (49-51%) and SPTB (31-33%)—resulting in spherical, poorly deformable erythrocytes that are trapped and destroyed in the spleen. 1, 2
Genetic Architecture
Primary Gene Mutations
The disease results from defects in five membrane protein genes, with distinct frequencies:
- ANK1 (ankyrin-1): 49-51% of cases 2, 3
- SPTB (beta-spectrin): 31-33% of cases 2, 3
- SLC4A1 (band 3): 13-18% of cases 2, 4
- SPTA1 (alpha-spectrin): 3.6-5% of cases 2, 4
- EPB42 (protein 4.2): Rare 1
Most mutations are unique to individual families—no common HS-associated mutations have been identified, making genetic testing complex but increasingly valuable 1. Recent cohorts have identified that 76.7% of detected variants are novel, continuously expanding the mutational spectrum 4.
Inheritance Patterns
- Autosomal dominant: Most common pattern
- De novo mutations: Occur in approximately 25-46% of families 5
- Autosomal recessive: Rare, typically associated with SPTA1 mutations and severe phenotype 2
Clinical Presentation
Classic Triad
Age-Related Severity
Children ≤3 years demonstrate significantly more severe anemia with lower RBC counts, hemoglobin levels, and reticulocyte counts compared to older children 4. This reflects the developmental maturation of compensatory mechanisms.
Genotype-Phenotype Correlations
Gene-Specific Clinical Patterns
SLC4A1-HS patients have the mildest phenotype: highest hemoglobin, lowest reticulocyte counts, lowest bilirubin, and none require splenectomy in childhood 2. This represents the most favorable genetic subtype.
SPTA1-HS (autosomal recessive) patients have the most severe phenotype: almost all require splenectomy in early childhood 2. These patients warrant aggressive monitoring and early intervention planning.
ANK1-HS patients show more severe anemia than SPTB-HS patients: significantly lower RBC counts (p=0.021) and hemoglobin (p<0.01) 3. Within ANK1 mutations, variants in the death domain are associated with lower MCV and MCH compared to other ANK1 domains 5.
Important Caveat
Within each gene, specific variant type or location does not reliably predict disease severity or likelihood of splenectomy 2. Variable expressivity occurs even among family members with identical mutations, including documented cases in twins 5.
Diagnostic Approach
Laboratory Hallmarks
- Elevated MCHC (>36 g/dL): Characteristic diagnostic feature 7
- Spherocytes on peripheral smear 1
- Elevated reticulocyte count (reflecting compensatory erythropoiesis) 7
- Undetectable haptoglobin 7
- Elevated indirect bilirubin and LDH 7
Specialized Testing
- Eosin-5-maleimide (EMA) binding test: Reference screening test 6, 8
- Acidified glycerol lysis test (AGLT): Alternative screening method 6
- Next-generation sequencing: Provides definitive molecular diagnosis in 97% of cases 2, 6
Genetic testing is particularly valuable in patients without family history (where 25-46% have de novo mutations) and helps predict clinical phenotype for family counseling 2, 5.
Modern Hematology Analyzer Parameters
Newer automated parameters improve screening sensitivity 6:
- % Hyper-He (Sysmex): percentage of RBCs with hemoglobin >49 pg
- % Hyper (Advia): reflects RBC hyperchromia
- MicroR (Sysmex): percentage of RBCs <60 fL
- MSCV (Beckman Coulter): mean sphered corpuscular volume
Complications
Common Complications
- Cholelithiasis: Occurs in 36% of patients requiring cholecystectomy 2
- Hemolytic crises: Triggered by infections or stress 1
- Aplastic crises: Often parvovirus B19-related 1
- Hepatic iron overload: Can occur even without transfusions 7
Pregnancy Considerations
Anemia is more pronounced in non-splenectomized pregnant women, while splenectomized patients show greater hematologic stability 8. Most achieve term vaginal deliveries with appropriate antenatal care, and neonatal outcomes are generally favorable 8.
Management Implications
Splenectomy Decisions
Total splenectomy produces greater hemoglobin improvements than partial splenectomy (p=0.02) 2. However, 29% of genetically diagnosed patients undergo splenectomy in childhood, with timing and type requiring careful risk-benefit assessment 2.
Splenectomy is curative for hemolysis but should be undertaken only after careful assessment given infection risks 1. The genetic subtype helps guide this decision—SLC4A1 patients rarely need it, while SPTA1 patients almost universally require it 2.
Military and Occupational Considerations
HS does not disqualify adults from military service, but affected individuals may experience fatigue during strenuous physical activity despite compensated hemolysis 7. The autosomal dominant inheritance has important implications for offspring counseling 7.